LIVER CENTER

肝脏在健康中扮演着核心而复杂的角色，负责任 用于合成关键分子，维持代谢平衡，以及 排毒过程。肝病是导致 美国的死亡和他们的调查跨越了基础科学和 临床医学。在旧金山的加州大学， 肝脏是15个部门的科学家的主要研究重点。 和两个学院(医学和药剂学)，并在三个主要 大学校园(Moffitt-Long医院，旧金山总医院 医院和退伍军人事务医疗中心)。随着最近的 成立为Mt.锡安医疗中心在加州大学旧金山分校的校园中 预计中心项目最终将包括调查人员 那个网站也是。 肝脏中心成立于1975年，目前的核心中心 格式，用于融合个人研究计划 组成一个联盟，并通过以下方式促进跨学科研究 对核心设施的支持、新举措的资金、浓缩 活动(包括访问科学家和小型休假计划)， 以及非常成功的年度静修。中心核心设施，其中 他们动物，分子生物学，肝细胞培养，肝脏灌流， 显微镜、生物统计学和质谱学提供了重要的 在本供资期间向中心调查人员提供的服务。新的 研究方向已经出现，目前的重点领域包括 细胞生物学、药物代谢和毒性方面的基础和临床研究， 肝纤维化和肝硬变，免疫学和移植， 代谢、运输、胆汁分泌和病毒性肝炎。这项研究 基数大幅增长，反映了 几个因素，包括坚定的机构承诺，继续 肝移植计划的成功运作，并不断增加 跨学科协作。 下一个供资期间的目标包括进一步扩大使用 分子和遗传学实验方法及其易化 临床研究，包括人体材料的研究。为此， 建议的主要核心设施改变包括扩建 分子生物学核心设施，并建立新的临床和 生物统计学核心设施。D.M.比塞尔博士，目前是一个中心 副主任，将担任联席主任。该中心享有 加州大学旧金山分校领导层的持续支持，它将继续在那里 被认可为对消化系统疾病研究和研究的重大贡献 作为国家资源提供珍稀动物或试剂和 专门技术方面的培训。预计在此期间， 未来五年，该中心将促进增加临床和 解决具体问题的分子方法的实验室应用 在人类肝脏生物学和疾病方面，包括对发病机制的研究 肿瘤和非肿瘤性疾病，诊断方法的发展 和试剂，以及医疗和外科治疗的创新。

The liver plays a central and complex role in health, being responsible for synthesis of key molecules, maintenance of metabolic balance, and detoxification processes. Liver diseases are among the leading causes of death in the United States and their investigation spans basic science and clinical medicine. At the University of California, San Francisco, the liver is a major focus of study among scientists in fifteen Departments and two Schools (Medicine and Pharmacy) and is represented on three major campuses of the University (Moffitt-Long Hospital, San Francisco General Hospital, and the Veterans Affairs Medical Center). With the recent incorporation of Mt. Zion Medical Center among the UCSF campuses, it is anticipated that Center programs will eventually include investigators at that site as well. The Liver Center was established in 1975, assuming its current Core Center format in 1980, for the purposes of melding individual research programs into a consortium and of fostering interdisciplinary research through support of core facilities, funds for new initiatives, enrichment activities (including visiting scientists and mini-sabbatical programs), and the highly successful annual retreat. Center Core Facilities, among them Animals, Molecular Biology, Liver Cell Culture, Liver Perfusion, Microscopy, Biostatistics, and Mass Spectrometry, have provided important services to Center investigators during the present funding period. New research directions have emerged, and current areas of emphasis include basic and clinical studies in cell biology, drug metabolism and toxicity, hepatic fibrosis and cirrhosis, immunology and transplantation, metabolism, transport, bile secretion, and viral hepatitis. The research base has grown substantially, reflecting the favorable influences of several factors, including strong institutional commitment, continued successful operation of the liver transplantation program, and increasing interdisciplinary collaboration. Goals for the next funding period include further expansion of the use of molecular and genetic experimental approaches and the facilitation of clinical research, including the study of human materials. To this end, proposed major changes in core facilities include expansion of the Molecular Biology Core Facility, and establishment of a new Clinical and Biostatistics Core Facility. Dr. D.M. Bissell, currently a Center Associate Director, will assume the role of Co-Director. The Center enjoys the ongoing support of the leadership at UCSF, where it continues to be recognized for major contributions to digestive diseases research and serves as a national resource in providing rare animals or reagents and training in specialized techniques. It is anticipated that, during the next five years, the Center will facilitate increasing clinical and laboratory application of molecular approaches to address specific issues in human liver biology and disease, including studies of the pathogenesis of tumors and non-neoplastic disorders, development of diagnostic methods and reagents, and innovations in medical and surgical treatment.